Mexiletine hydrochloride is a non-selective voltage-gated sodium channel blocker; Class IB anti-arrhythmic compound.

Stavudine is a nucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.

Salsalate is a nonsteroidal anti-inflammatory drug (NSAID).

BP897 is a partially selective D3 dopamine receptor agonist.

Trk-IN-3 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 8.4 nM, 6.2 nM and 2.2 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

6-Hydroxy-DL-DOPA is a small-molecule that disrupts with RAD52 oligomerization, inhibits ssDNA binding by RAD52 with IC50 of 1.1 uM and by RAD52 (1 209) with IC50 of 1.6 uM.

Calhex-231 is a potent negative allosteric modulator of CaSR that blocks calcium-mediated activation with IC50 of 0.39 uM.

DC_AC50 (DCAC50) is a small molecule that inhibits the human copper chaperones Atox1 and CCS (Kd=6.8 and 8.2 uM), blocks copper trafficking and significantly attenuates cancer cell proliferation.

Edelfosine is a synthetic lysophospholipid analog that selectively inhibits PLC with IC50 of 9.6 uM in fibroblasts and adenocarcinoma cells.

CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively.

CRANAD-2 is a difluoroboron-derivatized curcumins as near-infrared probe for in vivo detection of amyloid-beta deposits. Upon interacting with Abeta aggregates, CRANAD-2 undergoes a range of changes, which include a 70-fold fluorescence intensity increase, a 90 nm blue shift (from 805 to 715 nm), and a large increase in quantum yield. Moreover, this probe also shows a high affinity for Abeta aggregates (K(d) = 38.0 nM), a reasonable log P value (log P = 3), considerable stability in serum, and a weak interaction with albumin. After intravenous injection of this probe, 19-month-old Tg2576 mice exhibited significantly higher relative signal than that of the control mice over the same period of time.

A286982 is an inhibitor that blocks the integrin-ligand interaction between leukocyte function-associated antigen-1 (LFA-1) and intercellular adhesion molecule-1.

MELK-T1 is a potent and selective inhibitor of protein kinase MELK.

Merimepodib(VX-497) is a novel noncompetitive inhibitor of IMPDH (Inosine monophosphate dehydrogenase).

MI-136 inhibits DHT-induced expression of androgen receptor (AR) target genes.

MI-503 is a highly potent and orally bioavailable small molecule inhibitor of the menin-MLL interaction.

MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

Migalastat hydrochloride (1-Deoxygalactonojirimycin hydrochloride) is a potent and competitive inhibitor of α-galactosidase A (α-Gal A) with an IC50 of 0.04 μM for human α-Gal A.

Mirin is a Mre11-Rad50-Nbs1 (MRN)-ATM pathway inhibitor that blocks the 3' and 5' exonuclease activity associated with Mre11.

Mirogabalin (DS-5565) is a novel, preferentially selective α2δ-1 ligand characterized by high potency and selectivity to the α2δ-1 subunit of voltage-sensitive calcium-channel complexes in the CNS.

Mitapivat is an activator of pyruvate kinase isoenzyme M2 (PKM2),

MK-4101 is a potent SMO Inhibitor of the Hedgehog Pathway, highly active against Medulloblastoma and Basal Cell Carcinoma.

MK-4827 is an inhibitor of poly (ADP-ribose) polymerase (PARP) with potential antineoplastic activity.

MK-7246 is a potent and selective CRTH2 antagonist with a Ki of 2.5±0.5 nM.

MK-8998 is a novel bioactive compound for the treament of psychiatric disease.

Epiblastin A is a Casein Kinase 1 (CK1) inhibitor. Epiblastin A engages CK1 isoenzymes in cell lysate and induces efficient conversion of epiblast stem cells (EpiSCs) into embryonic stem cells (cESCs).

EC23 is a fluorescent, voltage, indicator, action, potentials, mammalian, neurons, perturbations, cardiac, waveform, pluripotent, stem, cell-derived, cardiomyocytes

GNE-140 racemic is a novel potent lactate dehydrogenase (LDHA) inhibitor. In MIA PaCa-2 human pancreatic cells, LDHA inhibition rapidly affected global metabolism, although cell death only occurred after 2 d of continuous LDHA inhibition. Pancreatic cell lines that utilize oxidative phosphorylation (OXPHOS) rather than glycolysis were inherently resistant to GNE-140, but could be resensitized to GNE-140 with the OXPHOS inhibitor phenformin. Acquired resistance to GNE-140 was driven by activation of the AMPK-mTOR-S6K signaling pathway, which led to increased OXPHOS, and inhibitors targeting this pathway could prevent resistance.

SEMBL is a potent NF-κB inhibitor that inhibits DNA binding of NF-κB component p65.

VU0155094 is a potent, selective pan-Group III mGlu positive allosteric modulator with IC50 of 3.43/1.5/0.93 uM for mGlu8/7/4, respectively.